News

A week dedicated to raising awareness, analyzing the effects of the pandemic on public mental health, and building a space for debate. These are the main objectives of the initiatives organized by Angelini Pharma on the occasion of World Mental Health Day, our Mental Health Week.

The results of the study have been published online by the journal Epilepsia.

In this issue, you can find exciting news and original stories, a focus on our journey towards on Digital Health and our commitment to striving for excellence through our Strategic Imperative Operational Excellence.

The launch of the new Career Site is part of an employer branding strategy that aims to attract the best candidates through the use of various communication tools and channels, as well as directly meeting young candidates through events organized in partnership with universities, business schools, and private entities.

In this issue, you'll find exciting news and original stories, a focus on our commitment on Epilepsy and our strategy to becoming a recognized Employer of Choice.

In 2020, billions of people faced a global pandemic for the first time in their lives, without having any experience or preparation for it. In this year everyone had to find new emotional, mental and physical resources. Angelini Pharma also wanted to do its part.

We are celebrating International Women's Day today, the annual opportunity to reflect on the progress achieved and call for greater gender equality changes.

Angelini Pharma never stops looking at future, with a foremost attention to innovative solutions and opportunities for identifying and enhancing promising health solutions.

On February 8th, the world celebrates International Epilepsy Day to raise awareness of one of the world's most prevalent neurological diseases.

Cenobamate has received a positive CHMP opinion for the adjunctive treatment of focal onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.